Health Economics›Melanoma›Metastatic or unresectable disease first-line

Metastatic or unresectable disease first-line

Melanoma · 19 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 7 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Dacarbazine and Ipilimumab Variant #01	—	R 1 574 625	84d	—	11.2 mo	8	R 4 735 467 PFS proxy	1
Ipilimumab monotherapy Variant #01	—	R 786 153	84d	4.4 mo	19.9 mo	4	R 3 144 612 PFS proxy	3
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	5.7 mo	39.5 mo	52	R 14 921 674 PFS proxy	4
Ipilimumab and Nivolumab Variant #01 Partial	—	R 78 615	42d	11.5 mo	72.0 mo	4	R 314 461 PFS proxy	4
ABC Variant #01	—	R 78 006	28d	—	—	~2	~R 156 012 indirect	—
Temozolomide and Bevacizumab Variant #01	—	R 43 070	28d	—	—	~2	~R 86 139 indirect	—
Carboplatin and nab-Paclitaxel (CnP) Variant #01	—	R 41 178	21d	~5.7 mo	~13.9 mo	~4	~R 164 713 PFS proxy · indirect	11
Carboplatin and Paclitaxel (CP) and Bevacizumab Variant #01	—	R 32 363	28d	4.8 mo	14.0 mo	7	R 224 167 PFS proxy	2
CVD (Vinblastine) Variant #01	—	R 8 684	21d	—	—	~4	~R 34 735 indirect	—
CVD (Vindesine) Variant #01 Partial	—	R 4 936	21d	—	12.0 mo	4	R 19 155 PFS proxy	—
Cisplatin, Dacarbazine, Paclitaxel Variant #01	—	R 4 704	21d	—	—	~2	~R 9 407 indirect	—
Dacarbazine and Vindesine Variant #01 Partial	—	R 4 347	28d	—	—	~2	~R 8 695 indirect	—
Cisplatin, Dacarbazine, IL-2, IFN alfa-2b +/- Carmustine Variant #01 Partial	—	R 2 760	21d	—	11.0 mo	6	R 16 559 PFS proxy	1
Cisplatin and Dacarbazine Variant #01	—	R 2 760	21d	—	9.5 mo	6	R 16 559 PFS proxy	1
Dacarbazine monotherapy Variant #01	—	R 2 608	21d	2.5 mo	8.4 mo	2	R 5 217 PFS proxy	7
Carboplatin and Paclitaxel (CP) Variant #02	—	R 1 025	21d	3.0 mo	10.2 mo	12	R 12 296 PFS proxy	3
Fotemustine monotherapy Variant #01 Partial	—	—	56d	—	~13.8 mo	~2	—	1
Nivolumab monotherapy Variant #01 Partial	—	—	14d	4.6 mo	34.1 mo	2	—	10
Nivolumab and Relatlimab Variant #01 Partial	—	—	28d	10.2 mo	52.2 mo	2	—	7

19 of 19 regimens shown